168 related articles for article (PubMed ID: 30410117)
21. Cyclic strain amplitude dictates the growth response of vascular smooth muscle cells in vitro: role in in-stent restenosis and inhibition with a sirolimus drug-eluting stent.
Colombo A; Guha S; Mackle JN; Cahill PA; Lally C
Biomech Model Mechanobiol; 2013 Aug; 12(4):671-83. PubMed ID: 22961302
[TBL] [Abstract][Full Text] [Related]
22. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
[TBL] [Abstract][Full Text] [Related]
23. [Experimental study of Mytrolimus-eluting stents on preventing restenosis in porcine coronary model].
Qiu H; Gao RL; Tang ZR; Meng L; Zhao H; Ruan YM; Zhao H; Yang YJ; Chen JL; Chen ZJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Jun; 33(6):561-4. PubMed ID: 16053797
[TBL] [Abstract][Full Text] [Related]
24. Cutting balloon combined with paclitaxel-eluting balloon for treatment of in-stent restenosis.
Kong J; Hou J; Ma L; Xing L; Jia H; Liu H; Zhang S; Yu B; Jang IK
Arch Cardiovasc Dis; 2013 Feb; 106(2):79-85. PubMed ID: 23527911
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of non-Ras protein farnesylation reduces in-stent restenosis.
Coats P; Kennedy S; Pyne S; Wainwright CL; Wadsworth RM
Atherosclerosis; 2008 Apr; 197(2):515-23. PubMed ID: 17662987
[TBL] [Abstract][Full Text] [Related]
26. Platelet-derived growth factor regulates vascular smooth muscle phenotype via mammalian target of rapamycin complex 1.
Ha JM; Yun SJ; Kim YW; Jin SY; Lee HS; Song SH; Shin HK; Bae SS
Biochem Biophys Res Commun; 2015 Aug; 464(1):57-62. PubMed ID: 26032503
[TBL] [Abstract][Full Text] [Related]
27. Effect of a novel peptide, WKYMVm- and sirolimus-coated stent on re-endothelialization and anti-restenosis.
Jang EJ; Bae IH; Park DS; Lee SY; Lim KS; Park JK; Shim JW; Sim DS; Jeong MH
J Mater Sci Mater Med; 2015 Oct; 26(10):251. PubMed ID: 26438653
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy.
Curcio A; Torella D; Indolfi C
Circ J; 2011; 75(6):1287-96. PubMed ID: 21532177
[TBL] [Abstract][Full Text] [Related]
29. Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition.
Wu BJ; Li Y; Ong KL; Sun Y; Shrestha S; Hou L; Johns D; Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2333-2341. PubMed ID: 29025709
[TBL] [Abstract][Full Text] [Related]
30. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy.
Martinet W; Verheye S; De Meyer GR
Autophagy; 2007; 3(3):241-4. PubMed ID: 17224626
[TBL] [Abstract][Full Text] [Related]
31. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation.
Wang Y; Bai Y; Qin L; Zhang P; Yi T; Teesdale SA; Zhao L; Pober JS; Tellides G
Circ Res; 2007 Sep; 101(6):560-9. PubMed ID: 17656678
[TBL] [Abstract][Full Text] [Related]
32. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
Hacker TA; Griffin MO; Guttormsen B; Stoker S; Wolff MR
J Invasive Cardiol; 2007 Jun; 19(6):269-74. PubMed ID: 17541129
[TBL] [Abstract][Full Text] [Related]
33. The behavior of vascular smooth muscle cells and platelets onto epigallocatechin gallate-releasing poly(l-lactide-co-epsilon-caprolactone) as stent-coating materials.
Cho HH; Han DW; Matsumura K; Tsutsumi S; Hyon SH
Biomaterials; 2008 Mar; 29(7):884-93. PubMed ID: 18031806
[TBL] [Abstract][Full Text] [Related]
34. Effects of elemene on inhibiting proliferation of vascular smooth muscle cells and promoting reendothelialization at the stent implantation site.
Sun W; Huang Y; Yin T; Wang J; Du R; Qiu J; Zhang Y; Wang Y; Chen J; Wang G
Biomater Sci; 2017 May; 5(6):1144-1155. PubMed ID: 28503689
[TBL] [Abstract][Full Text] [Related]
35. Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis.
Zamani M; Prabhakaran MP; Varshosaz J; Mhaisalkar PS; Ramakrishna S
Acta Biomater; 2016 Sep; 42():316-328. PubMed ID: 27397493
[TBL] [Abstract][Full Text] [Related]
36. Comparison of dextran-based sirolimus-eluting stents and PLA-based sirolimus-eluting stents in vitro and in vivo.
Lee SY; Bae IH; Park DS; Jang EJ; Shim JW; Lim KS; Park JK; Sim DS; Jeong MH
J Biomed Mater Res A; 2017 Jan; 105(1):301-310. PubMed ID: 27615559
[TBL] [Abstract][Full Text] [Related]
37. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.
Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M
Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312
[TBL] [Abstract][Full Text] [Related]
38. Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model.
Buszman PP; Michalak MJ; Pruski M; Fernandez C; Jelonek M; Janas A; Savard C; Gwiazdowska-Nowotka B; Żurakowski A; Wojakowski W; Buszman PE; Milewski K
Cardiol J; 2016; 23(6):657-666. PubMed ID: 27976797
[TBL] [Abstract][Full Text] [Related]
39. Secreted Matrix Metalloproteinase-9 of Proliferating Smooth Muscle Cells as a Trigger for Drug Release from Stent Surface Polymers in Coronary Arteries.
Gliesche DG; Hussner J; Witzigmann D; Porta F; Glatter T; Schmidt A; Huwyler J; Meyer Zu Schwabedissen HE
Mol Pharm; 2016 Jul; 13(7):2290-300. PubMed ID: 27241028
[TBL] [Abstract][Full Text] [Related]
40. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design.
Steffel J; Latini RA; Akhmedov A; Zimmermann D; Zimmerling P; Lüscher TF; Tanner FC
Circulation; 2005 Sep; 112(13):2002-11. PubMed ID: 16172265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
